Canaccord raised the firm’s price target on TransMedics to $117 from $102 and keeps a Buy rating on the shares. The firm said management also called for sustained profitability and of note was the company’s commentary on working on a cold perfusion product for heart to address the standard DBD Heart market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: